Cost effectiveness and health-related quality of life of chemoradiotherapy versus radiation therapy alone in elderly head and neck cancer patients

Tanja Sprave1,2 · Vivek Verma3 · Alexander Fabian1,2,4 · Alexander Rühle1,2 · Dimos Baltas1,2 · Anca-Ligia Grosu1,2 · Nils H. Nicolay1,2

Received: 28 March 2022 / Accepted: 20 June 2022 / Published online: 14 July 2022 © The Author(s) 2022

Abstract

Purpose Radiotherapy (RT) constitutes a mainstay in the treatment of elderly patients with head and neck cancer (HNC), but use of simultaneous chemoradiotherapy (CRT) remains controversial. We have conducted a prospective analysis based on real-world patient data to examine the health-related quality of life (HRQoL) and cost effectiveness (CE) of CRT vs. RT in elderly HNC patients.

Methods Eligible participants ≥65 years treated in a large tertiary cancer center between July 2019 and February 2020 who completed the validated EQ-5D-5L questionnaire (health state index [HI] and visual analog scale [VAS]) before and after RT were included. CE referred to direct medical costs, including diagnosis-related group (DRG)-based billings for inpatients and uniform assessment standard (EBM)-based costs for outpatients. The primary endpoint was cost (euros [€]) per quality-adjusted life year (QALY). The incremental cost-effectiveness ratios (ICERs) were calculated. Costs and QALYs were not discounted for short overall survival (OS).

Results Baseline HRQoL was 0.878 (±0.11) in the CRT group and 0.857 (±0.17) in the RT group. Upon completion of therapy, HRQoL amounted to 0.849 (±0.14) in the CRT and 0.850 (±0.13) in the RT group. The mean treatment-related cost in the CRT cohort was €22,180.17 (±8325.26) vs. €18,027.87 (±26,022.48) in the RT group. The corresponding QALYs amounted to 2.62 in the CRT and 1.91 in the RT groups. The ICER was €5848.31.

Conclusion This is the first analysis from the German health care system demonstrating that the addition of chemotherapy to RT for selected elderly HNC patients is cost effective and not associated with a significant HRQoL decline.

Keywords Head and neck squamous cell carcinoma · Geriatric patients · Chemoradiation · EQ-5D · Quality-adjusted life year

Introduction

The incidence of head and neck cancers (HNC) in elderly individuals is expected to rise considerably over the next decades [1, 2]. Curative treatment of elderly HNC patients often requires multimodal approaches including surgery, radiotherapy (RT), or concomitant chemoradiation (CRT), but therapy is often complicated by reduced patient performance or comorbidities. Additionally, treatment-related toxicities commonly require intensified medical procedures and additional supportive care in elderly patients, resulting in substantial healthcare resource requirements and costs [3–6]. In this respect, it is important to compare increased treatment-related costs to benefits in treatment outcomes and patients’ health-related quality of life (HRQoL) [7–9].
A key controversy for elderly patients undergoing definitive RT as a curative treatment relates to the addition of concomitant chemotherapy: although concomitant systemic treatment results in an additional improvement in patient survival, this benefit decreases with age and was no longer detectable in patients ≥ 70 years in the MACH-NC meta-analysis [10, 11]. Based on these data, it has long been debated whether age alone is a determining factor for treatment choice in elderly HNC patients [12, 13]. Considering the onset of potentially severe chemotherapy-induced toxicities in this vulnerable patient group, the questionable benefits of adding chemotherapy must be carefully weighed against its negative impact on patients’ quality of life and resulting cost-effectiveness (CE) [14, 15]. To date, only very limited data are available investigating HRQoL and resulting CE in elderly HNC patients [16–18]; for example, the French ELAN initiative is currently investigating the benefit of different chemotherapy protocols for fit and unfit elderly HNC patients with recurrent or metastatic disease within their trial program [19, 20].

Currently, a number of validated and internationally recognized approaches exist for measuring HRQoL based on the calculation of quality-adjusted life years (QALYs) [21–25]. Combining gains in patient outcomes and quality of life in a single metric allows comparison between different interventions as well as computation of incremental costs and CE [26, 27]. In this context, the EQ-5D, as a standardized measure of HRQoL, has been widely employed for health economy evaluations in the elderly [28, 29].

Using this validated tool, we aimed to prospectively evaluate and compare HRQoL and resulting CE of curative platinum-based CRT compared to RT alone in elderly HNC patients.

Patients and methods

Patients and treatment

The current study was approved by the Independent Ethics Committee of the Medical Faculty at the University of Freiburg (record no. 389/19), and written informed consent was obtained from all patients who agreed to participate. All patients aged ≥ 65 years receiving curative RT for HNC between July 2019 and February 2020 at the Department of Radiation Oncology, University Medical Center Freiburg, were screened for this analysis.

Demographic and treatment characteristics were obtained from the electronic patient records. Based on imaging and pathology, tumor nomenclature was performed according to the 8th edition of the TNM classification of malignant tumors. Individuals with a smoking history of at least 10 pack years were considered as smokers.

Treatment for all elderly HNC patients was based on multidisciplinary tumor board recommendations. Briefly, curative CRT was recommended in the definitive or adjuvant setting for locally advanced and inoperable tumors. Adjuvant cases were eligible for CRT based on histologically confirmed positive resection margins and/or extranodal/extracapsular spread. The standard dose for definitive CRT was 70 Gy EQD2 to the primary tumor, whereas patients undergoing adjuvant or repeat RT received 60–66 Gy EQD2 to the tumor cavity. RT was performed using intensity-modulated radiotherapy (IMRT) and image guidance (IGRT).

Health-related quality of life questionnaires

All patients aged ≥ 65 years receiving curative RT for HNC between July 2019 and February 2020 at the Department of Radiation Oncology, University Medical Center Freiburg, were asked to complete the EQ-5D-5L questionnaire before and after RT. The EQ-5D-5L is a generic quantitative measure for the generated health state index (HI) score and perceived health. It has been validated and is recommended for health technology assessment by the National Institute for Health and Clinical Excellence. The first descriptive component of the questionnaire pertains to the health state index (HI), as related to the five dimensions of mobility, self-care, daily activities, pain, and anxiety. Each parameter can be quantified on a five-grade scale (no, slight, moderate, severe, and extreme problems/inability). The second component of the questionnaire provides a visual analogue scale (VAS) for perceived overall health ranging from 0 to 100 (corresponding to the worst to the best imaginable health).

Statistical analysis

Statistical analyses of clinical and sociodemographic data were conducted with IBM SPSS Statistics software version 25 (IBM, Armonk, NY, USA). Descriptive statistics of the HI and VAS values were done in accordance with published guidelines. Normal distributions were tested using the Shapiro–Wilk test. Mann–Whitney U tests and chi-square tests were performed to assess potential differences between the different treatment groups and within each group. A two-tailed \( p < 0.05 \) was considered statistically significant for all analyses.

CE analysis focused on direct costs from the hospital’s perspective, as all patients in our cohort were retired and did not incur significant external costs. The detailed radiotherapy-associated treatment costs for each patient were based on diagnosis-related groups (DRG) of the German statutory health insurance for all inpatient treatments and based on the uniform assessment standard (einheitlicher Bewertungsmaßstab [EBM]) for 2019 and 2020 for all outpatient treat-
ments. Incremental cost-effectiveness ratios (ICERs) were calculated according to the following formula:

\[
\frac{\text{cost}_{\text{CRT}} - \text{costs}_{RT}}{\text{QALY}_{\text{CRT}} - \text{QALY}_{RT}}
\]

**Results**

**Patient population**

A total of 126 HNC patients ≥65 years scheduled for concomitant CRT presented to our center between July 2019 and February 2020 and were screened for this analysis. 46 patients were excluded as they presented for a second opinion and did not undergo RT at our department. 44 additional patients did not fill out all items in the baseline and posttreatment questionnaires and were excluded from this study. For 36 patients, all items in both questionnaires were available for further analysis (Fig. 1).

Based on tumor stage and/or histopathological risk factors such as incomplete resection or extracapsular spread, CRT had been recommended in all patients, but due to pre-existing comorbidities, concomitant chemotherapy was omitted in 18 patients (50%) as per the discretion of the treating physicians. Patients were predominantly male in both groups (CRT: \( n=13 \), 72.2%; RT: \( n=12 \), 66.7%; \( p=0.748 \)) with a median Charlson Comorbidity Index of 7 points in each group (\( p=0.714 \)). The median age was significantly lower in the CRT group and amounted to 71 years (65–88 years) vs. 81 years in the RT group (range 65–89 years, \( p=0.047 \); Table 1). Most patients were smokers (CRT: \( n=12 \), 66.7%; RT: \( n=7 \), 38.9%; \( p=0.095 \); chi-square test).

In the CRT group, 16 patients (88.9%) received definitive and 2 patients (11.1%) received adjuvant treatment. In the RT group, 11 (61.1%) and 7 patients (38.9%) received definitive and adjuvant therapy, respectively (\( p=0.054 \); chi-square test). All patients in the CRT group required an inpatient admission for median 26 (range 9–55) days, whereas in the RT group, only 10 patients (55.6%) required supportive inpatient admission (\( p=0.002 \)).

**Acute toxicities**

Acute RT-related toxicities were assessed at the end of treatment according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE v5.0). In summary, rates of treatment-related higher-grade (≥grade 3) acute toxicities were similar, and included dysphagia in 2 patients in each group, along with oral mucositis and xerostomia in 1 patient per group. There were no acute grade 4 or 5 toxicities in either group. Detailed toxicity rates are shown in Table 2.

**Health state index and visual analog scale**

For the CRT cohort, the mean EQ-5D-5L HI score before and after treatment was 0.878 ± 0.11 and 0.849 ± 0.14, respectively. In the group with RT alone, the HI scores amounted to 0.857 ± 0.17 and 0.850 ± 0.13, respectively (Table 3). The corresponding mean VAS scores were 67.61 ± 21.4 and 65.0 ± 22.9 in the CRT group vs. 72.50 ± 24.5 and 62.78 ± 16.2 in the RT group, respectively (Table 3). Changes in the HI were not significant in either group (\( p=0.361 \); for the CRT cohort and \( p=0.370 \) for the RT cohort). Similarly, HI did not significantly differ between groups at baseline (\( p=0.999 \)) or at completion of therapy (\( p=0.844 \)).

As shown in Table 3, there was no significant decline in the VAS scores within the CRT group from baseline to the end of treatment (\( p=0.361 \)); however, VAS scores in the RT group significantly deteriorated from baseline to completion (\( p=0.015 \)). The differences in VAS score between the CRT
Table 1 Baseline characteristics of the study population

|                        | RT  | RCT  | p-value |
|------------------------|-----|------|---------|
| All (n = 36)           | 18  | 18   |         |
| Age (years; median, range) | 81  | 71   | 0.047a  |
| Wave 1                 | 65–89 | 65–88 |         |
| Sex                    |     |      |         |
| Female                 | 6   | 5    | 0.748b  |
| Male                   | 12  | 13   |         |
| Smoking                |     |      |         |
| No                     | 11  | 6    | 0.095b  |
| Yes                    | 7   | 12   |         |
| Localization           |     |      |         |
| Nasopharynx            | 1   | 2    | 0.642b  |
| Oropharynx             | 3   | 7    |         |
| Hypopharynx            | 5   | 4    |         |
| Oral cavity            | 1   | 1    |         |
| Salivary glands        | 2   | 1    |         |
| Others                 | 6   | 3    |         |
| Histology              |     |      |         |
| Squamous cell carcinoma| 16  | 16   | 0.388b  |
| Adenocarcinoma         | 1   | 0    |         |
| Undifferentiated       | 0   | 1    |         |
| Others                 | 1   | 1    |         |
| Grading                |     |      |         |
| 1                      | 0   | 0    | 0.026b  |
| 2                      | 17  | 10   |         |
| 3                      | 1   | 7    |         |
| 4                      | 0   | 1    |         |
| Extranodal/extracapsular spread | | | |
| No                     | 13  | 17   | 0.074b  |
| Yes                    | 5   | 1    |         |
| Radiotherapy           |     |      |         |
| Definitive             | 11  | 16   | 0.054b  |
| Adjuvant               | 7   | 2    |         |
| Re-irradiation         | 4   | 4    |         |
| Radiotherapy technique |     |      |         |
| IMRT                   | 18  | 18   |         |
| Concomitant chemotherapy| 0  | 18   |         |
| Yes                    | 0   | 18   |         |
| Inpatient days (median, range) | 0  | 26   | 0.002a  |
| No                     | 10  | 18   |         |
| Secondary malignancy   |     |      |         |
| Yes                    | 8   | 4    | 0.298b  |
| No                     | 13  | 10   |         |
| Charlson score (median, range) |    | 7   | 0.714a  |
|                         | 5–12 | 4–17 |         |

*Mann–Whitney U test

bPearson chi-square test

and the RT groups were not significant at either baseline ($p=0.372$) or therapy completion ($p=0.389$).

The impact of clinical and pathological factors (chemotherapy, inpatient stay, extracapsular spread, smoking status, comorbidity index, total radiation dose, and acute treatment-related toxicities) on the treatment-related change in HRQoL was examined using multiple regression analysis. Increasing duration of inpatient stay decreased ($p=0.002$) and chemotherapy ($p=0.041$) increased intervals of HRQoL.

### Direct costs

The mean direct treatment costs in the CRT group amounted to 22,180.17 ± 8,325.26 € vs. 18,027.87 ± 26,022.48 € in the RT group. Treatment costs are outlined in Table 4.

### Quality-adjusted life years and incremental cost-effectiveness ratios

Overall survival (OS) estimation for both groups was based on published in-house data of elderly patients undergoing RT or CRT [30]. In this study, median OS in the CRT group was 37 months vs. 27 months in the RT group. The median OS in the CRT group at 37 months corresponded to 2.62 QALYs, whereas the OS in the RT group of 27 months corresponded to 1.91 QALYs. ICERs calculated as the incremental costs required for an additional QALY were €5,848,31, suggesting strong cost effectiveness for adding chemotherapy to RT in elderly HNC patients (Table 4). Costs and QALYs were not discounted for short OS [31].

### Discussion

Using prospective real-world data from the German healthcare system, this study demonstrated for the first time that curative CRT is highly cost effective compared to RT for selected elderly HNC patients [32]. To the best of our knowledge, no evidence has been published to date regarding the CE of cisplatin-based concomitant CRT for elderly HNC patients; therefore, no comparisons are possible regarding the CE in other healthcare systems. Considering the previously reported relevance of age regarding the benefits of concomitant chemotherapy in elderly HNC patients, our data support the notion that additional factors such as patient performance and comorbidities may strongly influence oncological outcomes and hence CE [10, 33]. One previous analysis comparing cisplatin-based CRT and RT from Brazil that did not focus on elderly HNC patients demonstrated the CE with an ICER of $3303 per life-year gained [34]. These findings are comparable to our results in elderly HNC patients, with an ICER of €5848.
Table 2  Acute radiotherapy-related toxicities according to the Common Terminology Criteria for Adverse Events (CTCAE v5.0)

| All (n = 36) | RT (n = 18) | RCT (n = 18) |
|-------------|-------------|-------------|
| CTCAE grade | 0 1 2 3     | 0 1 2 3     | p-value |
| Dermatitis  | 0 10 8 0    | 0 13 4 0    | 0.256   |
| Dysphagia   | 0 10 6 2    | 2 9 5 2     | 0.543   |
| Dysgeusia   | 4 10 4 0    | 3 9 5 0     | 0.761   |
| Nausea      | 10 0 1 0    | 14 3 1 0    | 0.193   |
| Mucositis   | 0 12 5 1    | 2 8 7 1     | 0.372   |
| Xerostomia  | 3 13 1 1    | 2 13 2 1    | 0.912   |
| Pain        | 8 5 5 0     | 10 4 3 0    | 0.669   |
| Hoarseness  | 16 2 0 0    | 15 3 0 0    | 0.630   |

Table 3  EQ-5D-5L health index and VAS values for elderly CRT and RT patients

| Baseline | RT end | p-value between groups | p-value within group |
|----------|--------|------------------------|---------------------|
| HI       | Mean (SD) | p-value between groups | Mean (SD) | p-value between groups | p-value within group |
| RT (n = 18) | 0.857 (0.17) | 0.999<sup>ac</sup> | 0.850 (0.13) | 0.844<sup>ad</sup> | 0.370<sup>b</sup> |
| RCT (n = 18) | 0.878 (0.11) | | 0.849 (0.14) | | 0.350<sup>b</sup> |
| VAS      | 0.372<sup>ac</sup> | | 0.389<sup>ad</sup> | | 0.015<sup>b</sup> |

RT radiotherapy, RCT chemoradiotherapy
<sup>a</sup>Mann–Whitney U test
<sup>b</sup>Wilcoxon signed-rank test
<sup>c</sup>RT vs. RCT group at baseline
<sup>d</sup>RT vs. RCT group at the end of therapy

Table 4  Real-world costs and QALYs for each group

| All (n = 36) | RT Mean (SD) | CRT Mean (SD) | p-value |
|-------------|--------------|---------------|---------|
| Health index| 0.850 (0.13) | 0.849 (0.14) | 0.844<sup>a</sup> |
| Costs (€)   | 18,027.87 (26,022.48) | 22,180.17 (8325.26) | – |
| Overall survival (months) | 27 | 37 | – |
| QALY’s      | 0.850×27=22.95:12=1.91 | 0.849×37=31.41:12=2.62 | – |

The bold values are the actual QALYs. The other numbers only serve as calculation values.
<sup>a</sup>Mann–Whitney U test

We believe that our findings may have an impact on decision-making processes regarding the choice of therapy in elderly HNC patients. It has to be considered that in our cohort, HRQoL did not significantly deteriorate towards the end of therapy despite increasing treatment-associated toxicities (Table 3). Additionally, highly comparable HI scores were calculated for patients undergoing CRT or RT upon completion of therapy. HI scores were in line with previously published data on HNC patients from our group, demonstrating HI scores of 0.84 directly after treatment and 0.85 at the 3- and 6-month follow-up examinations [35]. Notably, average HI values in the general German elderly population (≥65 years) range between 0.80 and 0.85 depending on the age cohort, and are strongly comparable to the HI data obtained in this study [36–38]. Calculation of HI values may depend on the type of HRQoL survey, but it has been demonstrated in a large Canadian analysis that converting HRQoL scores obtained from EORTC QLQ C30 and H&N35 questionnaires into EQ-5D-based scores results in highly comparable HI values in HNC patients [39, 40]. Similarly, the published VAS score for the general German elderly population amounts to 73.2, and gender-specific VAS values in females and males ≥70 years have been reported at 71.7 and 70.8, respectively, demonstrating data comparable to the patients included in this analysis [36, 41]. Comparable HRQoL values between the general German population and surviving elderly HNC patients undergoing CRT or RT have also been reported previously [15].

 Springer
As the EQ-5D-5L questionnaires are limited to testing only few health domains, there is a risk for demonstrating a premature optimal health level. Therefore, despite the ease of use of EQ-5D, the questionnaire has been criticized for its ceiling effect, and modifications have been performed to reduce this risk [42–46]. Compared to the previous EQ-5D-3L, the current EQ-5D-5L questionnaires demonstrated superior assessments and have therefore been recommended for general use as well as for HRQoL measurements in vulnerable cohorts with cancer and multiple comorbidities [45, 47]. The exact comparison of individual QoL questionnaires remains to be elucidated in a wider real-world clinical setting [48]. Especially considering the specific characteristics of elderly cancer patients, the performance of the EQ-5D questionnaire needs to be further evaluated against other QoL tools [36, 49].

A standardized recommendation for interpretation of patient-reported treatment-induced changes to evaluate the efficacy of an intervention in oncological patients has been established [50]. Notably, for elderly HNC patients, the lack of significant changes over time may represent a treatment benefit, as deteriorations resulting from locoregional tumor progression can be excluded [35, 50]. Thus, differences in HI values between baseline and the completion of treatment were calculated, and additional clinical and pathological factors influencing these treatment-induced changes were taken into consideration. Based on these analyses, we could demonstrate that an increasing duration of inpatient treatment reduced, and the application of concomitant chemotherapy increased intervals, suggesting a beneficial effect of prolonged inpatient stays and an adverse influence of concomitant chemotherapy administration on elderly HNC patients’ HRQoL. Due to administration of chemotherapy in the inpatient setting, significantly longer hospital stays were observed in the CRT group compared to the RT group. Very short hospital stays in the RT group may, in turn, explain the observed decline of the VAS score at the end of therapy, as no supportive treatments requiring hospitalization could be administered in outpatients, and outpatient supportive care may not be adequately effective in elderly HNC patients. These findings suggest the benefits of generous inpatient treatment in order to maintain an adequate HRQoL and underline the importance of closely monitoring elderly HNC patients during treatment.

Taken together, our data show a gain of 0.76 QALYs by adding concurrent chemotherapy to RT in elderly HNC patients, given a careful selection of this vulnerable patient cohort.

Our analysis has some limitations pertaining to the rather small sample size and the single-center collection of HRQoL data. Given the exploratory character of our study, an adequate sample size calculation was not possible, and numbers of elderly HNC patients scheduled for concomitant CRT were limited even at a tertiary cancer center. Therefore, it cannot be ruled out that the sample size did not allow for detection of small differences in HI scores based on the EQ-5D-5L questionnaires [51]. Another limitation is the absence of a control group, which was unfortunately not ethically feasible for this analysis. Additionally, we cannot rule out a selection bias, as the patients included in this analysis may represent overly comorbid or low-performing patients, or patients of a more advanced age who were transferred to a tertiary cancer center due to risk factors.

Our CE analysis is further limited by the fact that we could not model for a time horizon and account for costs of additional supportive interventions. As the analysis is based on German healthcare costs and the German billing system, there are limitations in transferring our findings to other countries and economic systems. Therefore, further interinstitutional research should expand these findings and corroborate our cost analyses of elderly HNC patients in the German healthcare setting.

In summary, our data provide evidence based on real-world data that curative CRT is cost effective compared to RT in selected elderly HNC patients in the German healthcare context. Further real-world ICERs are required from prospective studies with larger sample sizes in order to more precisely quantify the CE benefits.

Acknowledgements We would like to thank Marc Danner and Thomas Emler for their great support.

Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author Contribution T.S.: study conception and study design; T.S.: data acquisition and data analysis; T.S. and N.H.N.: statistical analysis, data interpretation, manuscript preparation, manuscript editing; T.S., V.V., A.F., A.R., D.B., A.L.G., N.H.N.: critical discussion of the manuscript.

Funding Open Access funding enabled and organized by Projekt DEAL.

Declarations

Conflict of interest T. Sprave, V. Verma, A. Fabian, A. Rühle, D. Balsas, A.-L. Grosu, and N.H. Nicolay declare that they have no competing interests.

Ethical standards The study was approved by the institutional ethical review committee (reference no. 389/19_201449).

For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are
References

1. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA (2009) Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 27:2758–2765

2. Vahl JM, Wigand MC, Denkinger M, Dallmeier D, Steiger C, Welke C et al (2021) Increasing mean age of head and neck cancer patients at a German tertiary referral center. Cancers 13:832

3. van den Bussche H, Kaduszkiewicz H, Schafer I, Koller D, Hansen H, Scherer M et al (2016) Overutilization of ambulatory medical care in the elderly German population?—An empirical study based on national insurance claims data and a review of foreign studies. BMC Health Serv Res 16:129

4. Heinrich S, Lupp M, Matschinger H, Angermeyer MC, Riedel-Heller SG, Konig HH (2008) Service utilization and health-care costs in the elderly. Value Health 11:611–620

5. Ebert N, Kensahe A, Lock S, Hadikwarta WW, Hansch A, Dorr W et al (2021) Results of a randomized controlled phase II trial: efficacy of polyphenol-containing cystus(R) tea mouthwash solution for the reduction of mucositis in head and neck cancer patients undergoing external beam radiotherapy. Strahlenther Onkol 197:63–73

6. Loser A, Ramke K, Grohmann M, Krause L, Roser P, Greinert F et al (2022) The impact of nutritional counseling on thyroid disorders in head and neck cancer patients after (chemo)radiotherapy: results from a prospective interventional trial. Strahlenther Onkol 198:135–148

7. Fleming I, Monaghan P, Gavin A, O’Neill C (2008) Factors influencing hospital costs of lung cancer patients in Northern Ireland. Eur J Health Econ 9:70–86

8. Saul KR, Franzini L, Lairson DR, Du XL (2012) Clinical and economic outcomes associated with adjuvant chemotherapy in elderly patients with early stage operable breast cancer. Value Health 15:72–80

9. Tribius S, Haladyn S, Hanken H, Busch CJ, Krall A, Petersen C et al (2021) Parotid sparing and quality of life in long-term survivors of locally advanced head and neck cancer after intensity-modulated radiation therapy. Strahlenther Onkol 197:219–230

10. Lacs B, Carmel A, Landais C, Wong SJ, Licitra L, Tobias JS et al (2021) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 107 randomized trials and 19805 patients, on behalf of MACH-NC group. Radiother Oncol 156:281–293. https://doi.org/10.1016/j.radonc.2021.01.013

11. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomized trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21–28

12. Derks W, de Leeuw JR, Hordijk GJ, Winnumbst JA (2005) Reasons for non-standard treatment in elderly patients with advanced head and neck cancer. Eur Arch Otorhinolaryngol 262:21–26

13. Mayer A, Wenzel W, Wollschläger D, Bostel T, Kruger M, Matthias C et al (2022) Adjuvant chemoradiotherapy in elderly patients with head and neck cancer: a monoinstitutional, two-to-one pair-matching analysis. Strahlenther Onkol 198:159–170

14. Bradley CJ, Dahmer B, Anscher M (2014) Prostate cancer treatment and survival: evidence for men with prevalent comorbid conditions. Med Care 52:482–489

15. Ruhl V, Hael E, Kalkekrathe T, Stoian R, Spohn SB, Sprave T et al (2021) Surviving elderly patients with head-and-neck squamous cell carcinoma—what is the long-term quality of life after curative radiotherapy?Cancers (Basel) 13(6):1275

16. Barbieri M, Weatherly HL, Ara R, Basarir H, Sculpter M, Adams R et al (2014) What is the quality of economic evaluations of non-drug therapies? A systematic review and critical appraisal of economic evaluations of radiotherapy for cancer. Appl Health Econ Policy 12:497–510

17. Medenwald D, Dietzel CT, Vordermark D (2018) Health services research in German radiation oncology: new opportunities to advance cancer care. Strahlenther Onkol 194:1097–1102

18. Tribius S, Meyer MS, Pfug C, Hanken H, Busch CJ, Krull A et al (2018) Socioeconomic status and quality of life in patients with locally advanced head and neck cancer. Strahlenther Onkol 194:737–749

19. Guigay J, Le Caer H, Ortholan C, Auperin A, Michel C, Mertens C (2019) Treatment of inoperable elderly head and neck cancer patients. Curr Opin Oncol 31:152–159

20. Guigay J, Mertens C, Le Caer H, Michel C, Ortholan C, Auperin A (2017) A French multicenter research program for a personalized treatment of elderly head and neck cancer patient. Bull Cancer 104:816–819

21. Devlin NJ, Parkin D, Browne J (2010) Patient-reported outcome measures in the NHS: new methods for analysing and reporting EQ-5D data. Health Econ 19:896-905

22. Jia H, Lubetkin EI, DeMichele K, Stark DS, Zack MM, Thompson WW (2018) Comparing the performance of 2 health utility measures in the medicare health outcome survey (HOS). Med Decis Mak 38:983–993

23. Nikolova S, Hulme C, West R, Pendleton N, Heaven A, Bower P et al (2020) Normative estimates and agreement between 2 measures of health-related quality of life in older people with frailty: findings from the community ageing research 75+ cohort. Value Health 23:1056–1062

24. Longworth L, Yang Y, Young T, Mulhern B, Hernandez Alava M, Mukuria C et al (2014) Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. Health Technol Assess 18:1–224

25. Brazier J, Ara R, Rowen D, Chevrou-Severac H (2017) A review of generic preference-based measures for use in cost-effectiveness models. Pharmacoeconomics 35:21–31

26. Tsuchiya A, Dolan P (2005) The QALY model and individual preferences for health states and health profiles over time: a systematic review of the literature. Med Decis Mak 25:460–467

27. McNamee P (2007) What difference does it make? The calculation of QALY gains from health profiles using patient and general population values. Health Policy 84:321–331

28. Cleland J, Hutchinson C, Khadka J, Milne R, Ratcliffe J (2019) A review of the development and application of generic preference-based instruments with the older population. Appl Health Econ Health Policy 17:781–801

29. Ludwig K, Graf von der Schulenburg JM, Greiner W (2018) German value set for the EQ-5D-5L. Pharmacoeconomics 36:663–674

30. Ruhl E, Haele H, Kalkekrathe T, Sprave T, Stoian R et al (2020) Radiotherapy for geriatric head-and-neck cancer patients: what is the value of standard treatment in the elderly? Radiat Oncol 15:31

31. Schad M, John J (2012) Towards a social discount rate for the economic evaluation of health technologies in Germany: an exploratory analysis. Eur J Health Econ 13:127–144
32. Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S et al (2015) Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol Assess 19:1–503, v–vi
33. Rühle A, Stromberger C, Haeli E, Senger C, David H, Stoian R et al (2020) Development and validation of a novel prognostic score for elderly head-and-neck cancer patients undergoing radiotherapy or chemoradiation. Radiother Oncol 154:276–282
34. Brentani A, de Castro G Jr., Federico MH (2011) Cost-effectiveness analysis of cisplatin-based chemoradiation to treat patients with unresectable, nonmetastatic head and neck cancer in Brazil. Head Neck 33:1199–1205
35. Sprave T, Zamboglou C, Verma V, Nicolay NH, Grosu AL, Lindenmeier J et al (2020) Characterization of health-related quality of life based on the EQ-5D-5L questionnaire in head-and-neck cancer patients undergoing modern radiotherapy. Expert Rev Pharmacoecon Outcomes Res 20:673–682
36. Marten O, Greiner W (2021) EQ-5D-5L reference values for the German general elderly population. Health Qual Life Outcomes 19:76
37. Konnopka A, Koenig HH (2017) The “no problems”-problem: an empirical analysis of ceiling effects on the EQ-5D 5L. Qual Life Res 26:2079–2084
38. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D et al (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 20:1727–1736
39. Pickard AS, De Leon MC, Kohlmann T, Cella D, Rosenbloom S (2007) Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients. Med Care 45:259–263
40. Leidl R, Reitmeir P (2011) A value set for the EQ-5D based on experienced health states: development and testing for the German population. PharmacoEconomics 29:521–534
41. Makai P, Brouwer WB, Koopmanschap MA, Stolk EA, Nieboer AP (2014) Quality of life instruments for economic evaluations in health and social care for older people: a systematic review. Soc Sci Med 102:83–93
42. Wyrwich KW, Norquist JM, Lenderking WR, Acaster S, Industry Advisory Committee of International Society for Quality of Life R (2013) Methods for interpreting change over time in patient-reported outcome measures. Qual Life Res 22:475–483
43. Garau M, Shah KK, Mason AR, Wang Q, Towse A, Drummond MF (2011) Using QALYs in cancer: a review of the methodological limitations. PharmacoEconomics 29:673–685